RxDoctor Payments Data

Claire Bruce

Gerontology · Huntsville, ALNPI 1245866417

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $10,598 of the $12,384 with a category attached, or 85.6%. It is spread thinly across 60 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. Among gerontology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,384in general payments, 2019–2025

Across 546 payments — averaging $22.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Inspire Medical Systems, Inc.$1K
  • GSK$855
  • Novartis$839
  • Johnson & Johnson$730
  • Boehringer Ingelheim$562
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$7256%
  • Travel & lodging$9778%
  • Food & beverage$10,59886%
  • Education$831%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)76$1,482
Inspire Medical Systems, Inc.2$1,246
GSK58$855
Novartis38$839
Johnson & Johnson16$730
Boehringer Ingelheim30$562
Pfizer27$452
Beigene USA, Inc.5$431
Seagen Inc.21$346
Regeneron Healthcare Solutions, Inc.15$305
Bristol Myers Squibb15$302
Daiichi Sankyo Inc.13$290
E.r. Squibb & Sons, L.L.C.18$283
Merck12$260
Grifols USA, LLC12$245
Insmed, Inc.9$208
Beone Medicines USA, Inc.10$181
Gilead(2 entities)10$177
Mylan Specialty L.p.10$174
Janssen Scientific Affairs, LLC4$156
Amgen8$147
Stemline Therapeutics Inc.5$121
Sanofi5$120
Ipsen Biopharmaceuticals, Inc4$114
Incyte Corporation5$112
Takeda Pharmaceuticals U.S.A., Inc.5$112
Karyopharm Therapeutics Inc.6$110
Jazz Pharmaceuticals Inc.5$106
AbbVie5$106
Lilly USA, LLC6$97
Eisai Inc.4$90
Blueprint Medicines Corporation4$87
Springworks Therapeutics, Inc.5$86
Array Biopharma Inc5$85
Genentech USA, Inc.4$76
Harmony Biosciences LLC4$75
Sobi, Inc3$74
La Jolla Pharmaceutical Company3$74
Puma Biotechnology, Inc.4$69
Adaptive Biotechnologies Corporation3$66
Pharmacyclics LLC, An Abbvie Company3$65
ADC Therapeutics America, Inc.3$64
Pharmaessentia USA Corporation3$62
United Therapeutics Corporation3$62
Astellas Pharma US Inc3$50
Bayer3$47
Sumitomo Pharma America, Inc.2$39
Tersera Therapeutics LLC2$38
Exelixis Inc.2$36
EMD Serono, Inc.2$36
Genmab U.S., Inc.2$36
Agios Pharmaceuticals, Inc.2$35
Acrotech Biopharma Inc.2$35
AVEO Pharmaceuticals, Inc.2$34
Mirati Therapeutics, Inc.2$31
Servier Pharmaceuticals LLC2$28
Iovance Biotherapeutics, Inc.1$27
Coherus Oncology, Inc.1$21
CTI Biopharma Corp.1$20
Rigel Pharmaceuticals, Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,384 in reported general payments places this provider in the 95th percentile of 143 gerontology providers in Alabama.

See all gerontology providers in Alabama

Medicare billing

Part B allowed, 2024
$20,003
Medicare patients
159
Services billed
254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate24$401,180
NubeqaDarolutamide20$259,991
XtandiEnzalutamide14$198,285
BrukinsaZanubrutinib12$179,504
ErleadaApalutamide12$167,339
EliquisApixaban76$84,196
OrgovyxRelugolix14$50,489
Anastrozole73$1,491
Hydroxyurea23$1,072
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen16$186
Dexamethasone12$120
Ondansetron Hcl11$100
Prednisone14$63
Furosemide11$10

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$1,482$401,18024 claims
BayerNubeqa$47$259,99120 claims
Astellas Pharma US IncXtandi$50$198,28514 claims
Beigene USA, Inc.Brukinsa$431$179,50412 claims
Johnson & JohnsonErleada$730$167,33912 claims
PfizerEliquis$452$84,19676 claims
Sumitomo Pharma America, Inc.Orgovyx$39$50,48914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 143 gerontology providers in Alabama.

Other gerontology in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →